Treatment of rheumatic diseases in patients with HCV and HIV infection

Mauro Galeazzi, Chiara Giannitti, Stefania Manganelli, Maurizio Benucci, Salvatore Scarpato, Chiara Bazzani, Roberto Caporali, Gian Domenico Sebastiani

Research output: Contribution to journalArticlepeer-review


A wide variety of rheumatic diseases has been documented in the presence of hepatitis C virus (HCV) infection and in human immunodeficiency virus (HIV) infection. In this conditions, physicians are refrained from using corticosteroids and/or immunosuppressants agents because of the risk of favouring viral replication and the progression of the underlying viral disease. In the present review we have focused our attention on the possible role of cyclosporine A (CsA), anti-Tumour Necrosis Factor (TNF) alpha agents in the treatment of HIV or HCV infected autoimmune patients. The results drown from the literature and from our personal experience confirm the safety of CsA and anti-TNF alpha agents, in terms of viral load and liver toxicity. A limited experience also suggest that both therapies can be given in combination in rheumatoid arthritis patients without increasing the risk of adverse events.

Original languageEnglish
Pages (from-to)100-103
Number of pages4
JournalAutoimmunity Reviews
Issue number2
Publication statusPublished - Dec 2008


  • Anti-TNF alpha agents
  • Autoimmune disorders
  • Cyclosporine A
  • HCV
  • HIV

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy


Dive into the research topics of 'Treatment of rheumatic diseases in patients with HCV and HIV infection'. Together they form a unique fingerprint.

Cite this